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Retroviral gene tagging is enjoying a renaissance as a gene discovery method since the completion of the draft mouse
genome sequence.The potential of this approach to elucidate the genetic basis of cancer is reviewed in the light of a series of
recent papers that report the results of high-throughput screens.
More than 20 years have elapsed since Hayward and col-
leagues first demonstrated that the c-myc proto-oncogene
could be activated by retroviral promoter insertion and that this
was a common event in the genesis of avian bursal lymphomas
(Hayward et al., 1981). Since that time, the search for common
retroviral insertion sites in cancer cells has been a highly pro-
ductive (if sometimes laborious) means to identify host cell
genes relevant to cancer. Retroviral replication entails the stable
integration of a DNA copy of the viral RNA genome into host cell
DNA, a process which is inherently mutagenic. The assump-
tions underlying the gene tagging strategy are that insertion is
essentially a random process and that the occurrence of multi-
ple insertions within a narrow genomic domain in independently
derived tumors provides evidence of a selective advantage to
cells bearing these insertions.With these defining criteria, many
common insertion sites (CIS) have been identified, leading to
the discovery of many host genes that are subject to mutation in
the carcinogenic process. The most commonly observed out-
come of insertional mutagenesis of CIS target genes is tran-
scriptional activation due to the insertion of viral promoters of
enhancer elements. In some cases viral integration disrupts the
translation unit, leading either to gain of function or inactivation.
Murine leukemia virus (MLV) models have been the most wide-
ly employed, as investigators have been attracted by the range
of retroviral isolates with tissue-specific oncogenic activity and
the availability of transgenesis as a means to establish the
oncogenic potential of the newly discovered CIS genes.
Moreover, the transgenic approach allows the combined effects
of candidate oncogenes to be tested in vivo, while the gene-tag-
ging process can be combined with transgenesis in a systemat-
ic and directed approach for the identification of specific collab-
orating gene sets (Jonkers and Berns, 1996).
The detection of the gene(s) affected by insertions at a CIS
has until recently been a slow process, often involving genome
walking from the clustered site and a painstaking search for the
affected transcription unit(s) over many kilobases of host DNA.
In some cases these difficulties have led to the search being
abandoned without discovery of a relevant target gene. This sit-
uation has changed radically following the advent of rapid PCR
cloning methods and the recent completion of the draft mouse
genome sequence. Together, these advances have reduced the
process of isolating and locating proviral insertion sites to a
comparatively straightforward exercise. The resulting resur-
gence of interest in retroviral gene tagging as a gene discovery
strategy is documented in a series of recently published papers
(Mikkers et al., 2002; Lund et al., 2002; Suzuki et al., 2002).
Collectively, these papers catalog over a hundred new loci
with potential relevance to cancer. Has this advance brought
within our grasp a comprehensive list of genes with the potential
to contribute to hematopoietic malignancy, along with an under-
standing of the genetic and biochemical pathways that link
them? It will certainly aid progress toward this goal, but there
are some gaps that must be filled before we can consider it
attainable. The significance of some of the new gene targets is
strongly reinforced by a degree of overlap between the three
studies and the close relatedness of some to established onco-
genes, including many that are involved in human cancer
(Suzuki et al., 2002). However, much of the newly published
data must be regarded as preliminary, as oncogenic signifi-
cance has yet to be confirmed for most of the novel CISs. The
standard of proof previously required for a single locus cannot
be waived merely because of the impressive size of the new
data sets.
A notable feature of all three studies is the very high fre-
quency of integrations at a small number of previously identified
targets, which overlap to some degree but are distinctive and
characteristic for each virus/host system. In contrast, the major-
ity of the new common insertion sites are defined by the minimal
criterion of only two hits within a specified “window” of genomic
DNA (30 kb). Moreover, even single insertions have been
scored where these have occurred at known oncogenes or their
homologs.The statistical argument that clustering is selected by
the oncogenic process depends on the assumption that the
process of retroviral insertion is close to random. This is an
issue that was debated and tested extensively prior to the avail-
ability of complete genome sequences (Weidhaas et al., 2000).
It must now be reexamined. Concerns that a nonrandom pattern
may apply are highlighted by a recent analysis of over 500 HIV
integrations in a human T cell line that exploits the draft human
genome sequence to reveal hot-spots of integration as well as a
preference for active genes, in the absence of any selection for
cellular growth advantage (Schroder et al., 2002). Indeed, a
number of the sites of HIV insertion might have been flagged for
potential oncogenic significance had they occurred in the MLV
studies. Hot-spots of the magnitude described for HIV, which
account for up to 1% of integrations, could not account for the
radical bias seen at some CISs where up to 90% of a tumor
cohort may display integrations at the same locus. They could,
however, generate a degree of noise in the system, particularly
at the low level of detection of many of the newly reported CISs.
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Moreover, if levels of gene activity also drive selection for MLV,
integration preference will be tissue specific and liable to evolve
during the carcinogenic process. An intriguing scenario can be
envisaged where activation of an initiating gene primes other
genes for targeting and leads to their selective activation as
secondary or progression events. While this speculative notion
would seem unlikely to undermine the general validity of gene
tagging as a means of identifying complementing oncogenes,
which is backed up by a large body of data, it illustrates the
need to follow up the initial observation of a new CIS with formal
evidence of its oncogenic consequences.
How many of the newly identified genes are functionally
important targets for activation (or inactivation)? Previous stud-
ies have shown that MLV can affect target gene expression over
several hundred kilobases (Lazo et al., 1990), suggesting that
some of the novel integrations might be targeting known rather
than new players in the oncogenic process. A candidate for
rationalization is HBS1, a gene on mouse chromosome 10 that
encodes a putative elongation release factor and was scored as
one of the most frequently targeted new CISs with a combined
total of 11 hits in two of the recent papers (Mikkers et al., 2002;
Lund et al., 2002). This gene is only 120 kb upstream of Myb
and is the closest gene to a previously identified CIS, fit-1(fti-1)
(Barr et al., 1999). Could insertions at this site be activating both
Myb and HBS1? A potentially telling observation is that these
two genes are coamplified in some cases of human pancreatic
cancer, but the fact that HBS1 is often missing from the amplifi-
cation unit has led to the argument that it is a passive partner in
this process, with Myb alone playing the essential oncogenic
role (Wallrapp et al., 1997).
How many hits of retroviral integration are required to con-
vert a normal cell to a fully malignant clone? Suzuki et al. report
up to six CISs hit in a single tumor (Suzuki et al., 2002),
although this is an exceptional case, while Mikkers et al. found
an average of 3.53 per tumor (Mikkers et al., 2002). It is unclear
whether these numbers have been corrected for clonal com-
plexity of the tumors, which can be assessed for lymphoid
tumors using the clonal markers of rearranged TCR and Ig
genes. This issue is important as oligoclonal tumors may con-
tain a series of independently transformed cells or clonal deriva-
tives of a single primary tumor that have acquired different sec-
ondary hits. Other recent studies shed light on this issue and on
possible limitations to the gene tagging approach in defining
oncogenic complementation groups, a concept that was first
elaborated in detail in studies of Eµ-myc mice by the Berns
group, who defined two groups of Myc collaborating genes by
neonatal MLV infection and screening for target genes in the
accelerated lymphomas (van Lohuizen et al., 1991). A comple-
mentation group is defined by genes that are subject to mutual-
ly exclusive targeting in the tumors (see also Mikkers et al.,
2002). This phenomenon is readily understood where it affects
partially redundant gene families such as the Pim kinases, but it
may also include distinct target genes such as Bmi-1 and Gfi-1,
two unlinked genes that are each flanked by extended clusters
of CIS (Gfi-1 here is shorthand for four closely linked CISs, 
eis-1pal-1/gfi1/evi-5) (Scheijen et al., 1997).
Figure 1 is distilled from two published studies that address
the targeting of known CISs in different oncogene transgenic
mouse strains (Scheijen et al., 1997; Blyth et al., 2001).
Accelerated Eµ-myc lymphomas display insertions at Pim fami-
ly genes and at the Bmi-1/Gfi-1 group. The reciprocal experi-
ment of gene tagging in Eµ-Pim-1 mice shows a remarkable
level of saturation with insertions at c-Myc or N-Myc and Pal-
1/Gfi-1 as secondary events in the vast majority of the tumors.
However, this apparently simple closed system of three collabo-
rating oncogenic pathways breaks down in virus-accelerated T
cell lymphomas of CD2-Runx2 transgenic mice (Blyth et al.,
2001). A Pim-like preference for activation of the Myc pathway
was noted in the Runx2 transgenic mice that display a highly
significant increase in the hit rate at Myc family genes com-
pared to their littermate controls (Figure 1). The fact that Pim1,2
and Pal-1/Gfi-1 loci are also targeted in these mice places the
Runx2 oncogene in a new complementation group that can syn-
ergize with either of the previously defined pathways. As the
Pim and Gfi-1 insertions did not overlap in these tumors, it
seems that targeting both pathways is no longer required when
Runx2 is the initiating gene and Myc is activated. However, it is
important to note that the lower hit rate at either gene group on
this background renders the lack of overlap statistically insignif-
icant. This problem highlights the difficulty we face in functional
grouping of the new CIS that are hit only rarely and have no
clear structural homologs.
What factors currently limit the spectrum of genes that can
be detected by the retroviral tagging approach? The exquisite
oncogenic specificity of the MLV family stems mainly from their
LTR enhancer elements that consist of unique and complex
arrays of binding sites for tissue-specific transcription factors
including Runx, Ets, and Myb (Lewis et al., 1999). The strong
selection for specific CIS targets must be due in part to the fact
that the relevant target gene promoters are among those most
amenable to activation by these enhancer elements. Moreover,
as many studies have shown that the spectrum and hit rate of
CIS is heavily influenced by mouse strain background, other as
Figure 1. Collaborating genes and complementation groups identified by
retroviral gene tagging in oncogene transgenic mice
The diagram, which is collated from two published studies (Scheijen et al.,
1997; Blyth et al., 2001), depicts the number of tumors affected by proviral
insertion at specific CISs in MoMLV induced tumors of Eµ-pim-1 (n = 43), Eµ-
myc (n = 85), CD2-Runx2 (n = 44), and control mice from the CD2-Runx2
cohort (n = 18). The colored bars indicate the frequency of hit at each
complementation group, as defined by mutually exclusive CISs. The over-
lap between bars indicates tumors that display insertions at CISs from both
complementation groups. The colored boxes at the foot are coded to indi-
cate the complementation group represented by the initiating oncogene
(transgene) in each case. A bracket underneath the two cohorts on the
right denotes comparison between transgenic and littermate controls in a
single study.
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yet unidentified genetic factors must be operative. This point
must be borne in mind as it generally invalidates statistical com-
parisons between studies.
Marked tissue-specific differences are also evident in the
interaction of MLVs with tumor suppressor pathways that may
be direct or indirect. While inactivation of the p53 gene in
Friend MLV-induced erythroleukemias has recently been
reevaluated and is proposed to be a prerequisite for tumor pro-
gression in vivo (Prasher et al., 2001), Moloney MLV favors the
development of lymphomas that retain functional p53 (Baxter
et al., 2001). The latter phenomenon may be reflected in the
low rate of loss of heterozygosity detected in Moloney induced
lymphomas (Lander and Fan, 1997), but this could not be
explained in terms of MLV insertion at specific loci, as the p53
null genotype had no significant impact on the hit rate at a num-
ber of CISs compared to littermate controls (Baxter et al.,
1996, 2001). Similar findings are now reported by Lund and
colleagues, who studied MLV tumors in Cdkn2A null mice.
These mice are defective for expression of the overlapping
gene products p16Ink4a and p19Arf, which regulate the Rb
and p53 pathways (Lund et al., 2002). The study revealed a
remarkable lack of effect of Cdkn2A deficiency on the hit rate at
oncogenes that are known to collaborate with this genotype
(such as Myc) (Eischen et al., 1999) or that might be expected
to fall into a Cdkn2A complementation group (e.g., Bmi-1/Gfi-1)
(Scheijen et al., 1997; Jacobs et al., 1999). The strongest skew
they detected affected the Tpl-2 gene, but it is notable that
these insertions were observed exclusively in histiocytic sarco-
mas, a novel tumor type seen only in the Cdkn2A background
(Lund et al., 2002). These results support our previous sugges-
tion that Moloney MLV gene tagging may have a “blind spot”
with respect to the targeting of certain tumor suppressor path-
ways in T-lymphoma cells (Baxter et al., 1996). Although we
have no definitive leads to the mechanism, Moloney MLV may
have evolved the capacity to suppress the Arf-p53 response in
T cells. If the effect is mediated in trans, this would account for
the apparent lack of requirement for specific insertion events
targeting the pathway.
The clearest example of the power and specificity of retro-
viral tagging in dissecting pathways is provided by the study
from Mikkers and colleagues who used Eµ-myc transgenic
mice deficient in both Pim-1 and Pim-2 to screen for genes that
would act as alternative targets in their absence (Mikkers et al.,
2002). Reassuringly, the new targets detected by this process
included the related Pim-3 gene and were able to be validated
by examination of the effects of insertion on gene transcription.
However, it will be noted that this heroic effort would not be
applied easily to other gene families where functional inactiva-
tion compromises viability.
These studies on MLV and HIV represent the first fruits of
whole genome sequences as applied to phenomena associat-
ed with retroviral integration. As similar high-throughput
screens are in progress in the public and commercial sectors,
publication of the details will be vital to allow rapid comparison
of data sets and assist in distinguishing integration preference
from selective processes operating on the infected cell. These
databases will also inform assessments of the potential haz-
ards of retroviral vector integration in the human genome and
hopefully aid the design of safer delivery systems for future
clinical application.
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